About: Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Background: Inflammatory immune processes have been clearly implicated in the etiopathology of schizophrenia. There are, however, only limited data dealing with immune parameters in the first episode patients with schizophrenia and the course of these parameters during treatment. Subjects and Methods: The presented study compared plasma levels of interleukin (IL)-6, IL-8, IL-10 and TNF-alpha in 25 patients with the first episode of schizophrenia with the minimal exposition of antipsychotics before and after treatment and with age and sex matched group of healthy volunteers. Changes in plasma cytokine levels were investigated after 4 weeks of treatment in relationship with the therapeutic outcome. Results: Our results show significantly increased plasma levels of IL-6 (p <= 0.001) and TNF-alpha (p <= 0.001) in patients at the admission in comparison with healthy volunteers. After 4 weeks of the treatment the PANSS score decreased (p <= 0.001), concurrently the plasma level of IL-6 decreased and TNF-alpha did not show any decrease after treatment. The patients' posttreatment and healthy control group comparison showed higher plasma levels of TNF-alpha (p=0.008) and marginally elevated plasma level of IL-6 (p=0.046) in the posttreatment group. Plasma levels of IL-8 and IL-10 did not show any significant differences. Conclusions: Our study validated the presence of the proinflammatory state in the first episode of schizophrenia. IL-6 may be considered as a state marker for acute exacerbations and TNF-alpha may be a trait marker of schizophrenia.
  • Background: Inflammatory immune processes have been clearly implicated in the etiopathology of schizophrenia. There are, however, only limited data dealing with immune parameters in the first episode patients with schizophrenia and the course of these parameters during treatment. Subjects and Methods: The presented study compared plasma levels of interleukin (IL)-6, IL-8, IL-10 and TNF-alpha in 25 patients with the first episode of schizophrenia with the minimal exposition of antipsychotics before and after treatment and with age and sex matched group of healthy volunteers. Changes in plasma cytokine levels were investigated after 4 weeks of treatment in relationship with the therapeutic outcome. Results: Our results show significantly increased plasma levels of IL-6 (p <= 0.001) and TNF-alpha (p <= 0.001) in patients at the admission in comparison with healthy volunteers. After 4 weeks of the treatment the PANSS score decreased (p <= 0.001), concurrently the plasma level of IL-6 decreased and TNF-alpha did not show any decrease after treatment. The patients' posttreatment and healthy control group comparison showed higher plasma levels of TNF-alpha (p=0.008) and marginally elevated plasma level of IL-6 (p=0.046) in the posttreatment group. Plasma levels of IL-8 and IL-10 did not show any significant differences. Conclusions: Our study validated the presence of the proinflammatory state in the first episode of schizophrenia. IL-6 may be considered as a state marker for acute exacerbations and TNF-alpha may be a trait marker of schizophrenia. (en)
Title
  • Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls
  • Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls (en)
skos:prefLabel
  • Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls
  • Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls (en)
skos:notation
  • RIV/00023752:_____/12:43913773!RIV13-MZ0-00023752
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, P(NT13843)
http://linked.open...iv/cisloPeriodika
  • Suppl.1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 141110
http://linked.open...ai/riv/idVysledku
  • RIV/00023752:_____/12:43913773
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • alpha; TNF; interleukin (IL) -6; inflammation; schizophrenia (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • HR - Chorvatská republika
http://linked.open...ontrolniKodProRIV
  • [2C8E5658341D]
http://linked.open...i/riv/nazevZdroje
  • Psychiatria Danubina
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 24
http://linked.open...iv/tvurceVysledku
  • Horáček, Jiří
  • Novák, Tomáš
  • Kubištová, Alžběta
http://linked.open...ain/vavai/riv/wos
  • 000309094600035
issn
  • 0353-5053
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 25 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software